Company Overview

Eli Lilly and Company is a global pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. The company operates primarily within the biopharmaceutical industry, with a strong emphasis on chronic and complex diseases. Its core therapeutic areas include diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular disease, which together represent the majority of its revenue base.

Founded in 1876, Eli Lilly has evolved from a small drug manufacturing enterprise into one of the world’s largest research-driven pharmaceutical companies. Its growth has been shaped by sustained investment in internal research and development, a vertically integrated manufacturing model, and a strategy centered on innovative biologics and specialty medicines. In recent years, the company has achieved a dominant market position in metabolic diseases, particularly diabetes and obesity, driven by differentiated injectable therapies and expanding global demand.

Business Operations

Eli Lilly operates through a single integrated pharmaceutical business model, with revenue generated from branded prescription medicines across multiple therapeutic franchises. Key business segments include Diabetes and Obesity, Oncology, Immunology, Neuroscience, and Cardiovascular Health, with diabetes and obesity representing the largest and fastest-growing revenue drivers. The company’s portfolio includes both small-molecule drugs and complex biologics, supported by in-house manufacturing and proprietary delivery technologies.

Operations span the full value chain, including research, clinical development, regulatory approval, manufacturing, and global commercialization. Eli Lilly maintains significant domestic operations in the United States alongside extensive international sales and manufacturing infrastructure. The company controls advanced biologics manufacturing assets and has expanded capacity to support injectable therapies. It also operates through wholly owned subsidiaries in major markets and maintains collaborations with academic institutions and biotechnology firms to support early-stage research.

Strategic Position & Investments

Eli Lilly’s strategic direction is centered on innovation-led growth, with a particular focus on high-impact chronic diseases and specialty indications with strong pricing power and long-term demand. The company continues to invest heavily in internal R&D while selectively pursuing acquisitions and licensing agreements to augment its pipeline. Recent strategy has emphasized scaling manufacturing capacity to meet global demand for metabolic disease therapies and accelerating late-stage clinical programs in oncology and neuroscience.

The company has made notable investments in emerging technologies such as RNA-based therapeutics, precision medicine, and next-generation biologics. Its portfolio includes several wholly owned development-stage subsidiaries and strategic equity investments that support platform technologies and novel drug modalities. Capital allocation priorities emphasize reinvestment in growth, disciplined business development, and shareholder returns through dividends rather than aggressive share repurchases.

Geographic Footprint

Eli Lilly is headquartered in Indianapolis, Indiana, and operates on a global scale with commercial, manufacturing, and research activities across North America, Europe, Asia-Pacific, Latin America, and parts of Africa. The United States remains the company’s largest market by revenue, driven by strong demand for branded specialty medicines and favorable market access.

Internationally, the company maintains a broad commercial presence in major developed and emerging markets, supported by regional subsidiaries and local partnerships. Manufacturing and research facilities are distributed across the United States, Western Europe, and Asia, providing operational resilience and supply chain diversification. Lilly’s global footprint allows it to influence international pharmaceutical markets while adapting to region-specific regulatory and pricing environments.

Leadership & Governance

Eli Lilly is led by an experienced executive team with a stated strategic vision centered on scientific excellence, patient-centric innovation, and long-term value creation. The company’s governance structure emphasizes strong board oversight, ethical business conduct, and alignment between executive compensation and performance outcomes.

Key members of the leadership team include:

• David A. Ricks – Chairman and Chief Executive Officer
• Anat Ashkenazi – Executive Vice President and Chief Financial Officer
• Patrik Jonsson – Executive Vice President and President, Lilly USA
• Ilya Yuffa – Executive Vice President and President, Lilly International
• Johna Norton – Senior Vice President, Global Regulatory Affairs
• Jacob S. Van Naarden – Executive Vice President, President, Oncology

The leadership team emphasizes disciplined capital allocation, accelerated innovation timelines, and responsible global expansion, reflecting a governance philosophy rooted in long-term sustainability and scientific leadership.